{"analyses":[{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.1","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.4"},{"ciLowerLimit":"2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.9","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"4.2"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-23.1","upperLimit":"27.7","value":"2.00"},{"groupId":"OG001","lowerLimit":"-10.0","upperLimit":"27.5","value":"4.01"},{"groupId":"OG002","lowerLimit":"-13.4","upperLimit":"21.8","value":"0.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"description":"Comparison of seizure-free days relative to baseline in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase","dispersionType":"Full Range","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","title":"Core Phase: Changes From Baseline in Number of Seizure-free Days","type":"SECONDARY","unitOfMeasure":"Number of seizure-free days -per 28 days"}